|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 57.65 USD | +0.87% |
|
+6.33% | +20.58% |
| 07-11 | Halozyme Therapeutics Insider Sold Shares Worth $3,387,517, According to a Recent SEC Filing | MT |
| 07-10 | AI Mania Masks Trade War Risks |  |
| Capitalization | 7.1B 6.08B 5.66B 5.28B 9.72B 611B 10.83B 68.23B 25.86B 286B 26.64B 26.09B 1,048B | P/E ratio 2025 * |
12.2x | P/E ratio 2026 * | 8.83x |
|---|---|---|---|---|---|
| Enterprise value | 7.51B 6.43B 5.98B 5.58B 10.27B 646B 11.45B 72.11B 27.34B 302B 28.16B 27.58B 1,108B | EV / Sales 2025 * |
6.04x | EV / Sales 2026 * | 4.5x |
| Free-Float |
98.92% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Halozyme Therapeutics, Inc.
More recommendations
More press releases
More news
| 1 day | +0.87% | ||
| 1 week | +6.33% | ||
| Current month | +10.82% | ||
| 1 month | +6.80% | ||
| 3 months | -6.09% | ||
| 6 months | +7.10% | ||
| Current year | +20.58% |
| 1 week | 56.06 |  | 58.14 |
| 1 month | 51.06 | | 58.14 |
| Current year | 47.5 | | 70.5 |
| 1 year | 42.01 | | 70.5 |
| 3 years | 29.85 | | 70.5 |
| 5 years | 25.17 | | 70.5 |
| 10 years | 6.96 | | 70.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
Helen Torley
CEO | Chief Executive Officer | 62 | 05/01/2014 |
Nicole LaBrosse
DFI | Director of Finance/CFO | 42 | 01/02/2022 |
Charles Theuer
CTO | Chief Tech/Sci/R&D Officer | 61 | 30/09/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Matthew Posard
BRD | Director/Board Member | 58 | 27/03/2013 |
Helen Torley
BRD | Director/Board Member | 62 | 05/01/2014 |
| Chairman | 60 | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.87% | +6.33% | +8.41% | +22.24% | 7.04B | ||
| -2.62% | +0.46% | -28.78% | -35.82% | 57.35B | ||
| +0.38% | -0.62% | -19.85% | -22.72% | 8.81B | ||
| -0.27% | +3.53% | +17.39% | +113.60% | 6.08B | ||
| -2.75% | +3.46% | +15.18% | +22.88% | 5.6B | ||
| +0.71% | +3.40% | +78.53% | +4.64% | 3.39B | ||
| +2.54% | +7.98% | +18.66% | +17.96% | 2.07B | ||
| +0.27% | +1.75% | -9.65% | +17.80% | 2.06B | ||
| +2.19% | +1.92% | +43.28% | -21.68% | 1.92B | ||
| +0.53% | +3.60% | +93.73% | +38.02% | 1.92B | ||
| Average | +0.18% | +3.64% | +21.69% | +15.69% | 9.62B | |
| Weighted average by Cap. | -1.50% | +1.63% | -10.68% | -12.03% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 1.24B 1.06B 991M 925M 1.7B 107B 1.9B 11.94B 4.53B 50.03B 4.66B 4.57B 183B | 1.5B 1.28B 1.19B 1.11B 2.05B 129B 2.28B 14.37B 5.45B 60.2B 5.61B 5.5B 221B |
| Net income | 597M 511M 476M 444M 817M 51.32B 910M 5.73B 2.17B 24.01B 2.24B 2.19B 88.04B | 811M 694M 646M 603M 1.11B 69.74B 1.24B 7.79B 2.95B 32.63B 3.04B 2.98B 120B |
| Net Debt | 404M 346M 322M 300M 553M 34.75B 616M 3.88B 1.47B 16.26B 1.52B 1.48B 59.62B | -367M -314M -292M -273M -502M -31.53B -559M -3.52B -1.33B -14.75B -1.37B -1.35B -54.09B |
More financial data
* Estimated data
Employees
350
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 14/07/25 | 57.65 $ | +0.87% | 1,099,406 |
| 11/07/25 | 57.15 $ | -0.83% | 1,242,856 |
| 10/07/25 | 57.63 $ | +1.86% | 1,617,625 |
| 09/07/25 | 56.58 $ | +1.40% | 1,556,825 |
| 08/07/25 | 55.80 $ | +2.91% | 2,268,977 |
Delayed Quote Nasdaq, July 14, 2025 at 09:00 pm
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
57.65USD
Average target price
65.67USD
Spread / Average Target
+13.91%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- HALO Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition